Study of Infigratinib in Children With Achondroplasia

This is a Phase 2, multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR) 1-3-selective tyrosine kinase inhibitor, in children 3 to 11 years of age with Achondroplasia (ACH) who previously participated in the PROPEL study (Protocol QBGJ398-001) for at least 6 months. The study includes dose escalation with extended treatment, and dose expansion. The study also includes a PK Substudy to fully characterize the pharmacokinetics of infigratinib in children with ACH.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Achondroplasia Bone Diseases Bone Diseases, Developmental Carbohydrate Metabolism, Inborn Errors Congenital, Hereditary, and Neonatal Diseases and Abnormalities Connective Tissue Diseases Dwarfism Endocrine System Diseases Genetic Diseases, Inborn Lysosomal Storage Diseases Metabolic Diseases Metabolism, Inborn Errors Mucinoses Mucopolysaccharidoses Mucopolysaccharidosis IV Musculoskeletal Diseases Nutritional and Metabolic Diseases Osteochondrodysplasias Skin and Connective Tissue Diseases

Age range

3 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Murdoch Children's Hospital, Parkville, Victoria, Australia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Signed informed consent by participant or parent(s) or legally authorized representative (LAR) and signed informed assent by the participant (when applicable).
Diagnosis of ACH, documented clinically and confirmed by genetic testing.
At least a 6-month period of growth assessment in the PROPEL study (Protocol QBGJ398-001) before study entry.
Ambulatory and able to stand without assistance
Able to swallow oral medication.

Exclusion criteria

Hypochondroplasia or short stature condition other than ACH.
In females, having had their menarche.
Height < -2 or > +2 standard deviations for age and sex based on reference tables on growth in children with ACH.
Significant concurrent disease or condition that, in the view of the Investigator and/or Sponsor, would confound assessment of efficacy or safety of infigratinib.
Current evidence of corneal or retinal disorder/keratopathy.
History of malignancy.
Currently receiving treatment with agents that are known strong inducers or inhibitors of CYP3A4 and medications which increase serum phosphorus and/or calcium concentration.
Treatment with growth hormone, insulin-like growth factor 1 (IGF-1), or anabolic steroids in the previous 6 months or long-term treatment (>3 months) at any time.
Treatment with a C-type natriuretic peptide (CNP) analog, fibroblast growth factor (FGF) ligand trap, or treatment targeting FGFR inhibition at any time.
Regular long-term treatment (>3 weeks) with oral corticosteroids (low-dose ongoing inhaled steroid for asthma is acceptable).
Treatment with any other investigational product or investigational medical device for the treatment of ACH or short stature.
Previous limb-lengthening surgery or guided growth surgery.
Fracture within 12 months of screening.

Treatment and study plan

Infigratinib 0.016 mg/kg

Drug

Initial cohort dose of infigratinib at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.